The University of Chicago Header Logo

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to Derman, Benjamin
Item TypeName
Concept Multiple Myeloma
Academic Article Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study.
Academic Article Clinician attitudes and practices toward measurable residual disease in multiple myeloma.
Academic Article Renal Dysfunction and Recovery following Initial Treatment of Newly Diagnosed Multiple Myeloma.
Academic Article Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.
Academic Article Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis.
Academic Article International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.
Academic Article Sex differences in outcomes in multiple myeloma.
Academic Article Recommendations and outcomes from a geriatric assessment guided multidisciplinary clinic prior to autologous stem cell transplant in older patients.
Academic Article Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation.
Academic Article Knowing the unknowns in high risk multiple myeloma.
Academic Article ATTR Cardiomyopathy Meets Multiple Myeloma: The Importance of Cardiac Biopsy.
Academic Article When a Monoclonal Gammopathy Is Not Multiple Myeloma.
Academic Article Clinician survey regarding measurable residual disease-guided decision-making in multiple myeloma.
Academic Article Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study.
Academic Article Longitudinal Real-World Neuropathy and Patient-Reported Outcomes With Bortezomib and Lenalidomide in Newly Diagnosed Multiple Myeloma.
Academic Article Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial.
Academic Article Genome-wide profiling of 5-hydroxymethylcytosines in circulating cell-free DNA reveals population-specific pathways in the development of multiple myeloma.
Academic Article Body Mass Index and Overall Survival of Patients with Newly Diagnosed Multiple Myeloma.
Academic Article A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma.
Academic Article Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma.
Concept Smoldering Multiple Myeloma
Academic Article Infection rates are high across the multiple myeloma continuum, not just with bispecific antibodies.
Academic Article Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial.
Academic Article Fair Allocation of Scarce CAR T-Cell Therapies for Relapsed/Refractory Multiple Myeloma.
Academic Article MRD-guided treatment cessation in multiple myeloma.
Academic Article Measurable Residual Disease and Decision-Making in Multiple Myeloma.
Academic Article International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma.
Academic Article Evaluation of administration-related reactions with subcutaneous daratumumab with and without premedication.
Academic Article Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone.
Academic Article Mass spectrometry-based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma.
Academic Article Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant.
Academic Article Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee.
Academic Article Improving Access to T-Cell Therapies in Multiple Myeloma.
Search Criteria
  • Multiple Myeloma